학술논문

Leveraging patient‐reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience
Document Type
article
Source
Cancer Medicine. 10(20)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Rare Diseases
Pancreatic Cancer
Cancer
Prevention
Digestive Diseases
Management of diseases and conditions
7.1 Individual care needs
Adult
Advertising
Aged
Aged
80 and over
Cancer Care Facilities
Feasibility Studies
Female
Humans
Male
Middle Aged
Pancreatic Neoplasms
Patient Participation
Patient Reported Outcome Measures
Precision Medicine
Registries
Research
United States
Young Adult
PanCAN
pancreatic cancer
patient-reported outcomes
registry
Biochemistry and Cell Biology
Oncology and carcinogenesis
Language
Abstract
BackgroundThe Pancreatic Cancer Action Network (PanCAN) Patient Registry is an online, pancreatic cancer-specific, global registry enabling patients to self-report sociodemographics, disease/management characteristics, and patient-reported outcomes (PROs). We sought to describe the creation, user experience, and research potential of the PanCAN Registry.MethodsWe obtained data to describe (1) the creation of the Registry (questionnaire development, marketing efforts, and regulatory considerations); (2) the user experience (user characteristics and interactions with the registry following inception); and (3) the research potential of the registry (comparing PROs and treatment patterns by age [±65 years] and treatment site [community or academic] for users with de novo metastatic disease).ResultsThe Registry was conceived as part of PanCAN's strategic plan for a personalized therapy initiative. PanCAN staff and disease expert consultants developed questionnaires hosted on an electronic PRO platform. Users had the option to include their data in research efforts, and the Registry platform received institutional review board approval. From 7/2015 to 12/2020, 2187 patients visited the registry and 1697 (77.6%) completed at least one survey (median age = 64 years [range: 24-90], 47.9% women, 88.7% White, 34.0% metastatic disease). Among patients with metastatic disease (N = 567), 46.0% were ≥65 years old and 67.5% received treatment at community sites. Patients ≥65 years reported feeling less hopeful about the treatment plan (12.4% vs. 24.3%, p = 0.003), and patients treated at community sites reported more frequent treatment breaks of >2 weeks (58.2% vs. 28.1%, p